400 related articles for article (PubMed ID: 20402760)
1. Guidelines for treatment of autoimmune neuromuscular transmission disorders.
Skeie GO; Apostolski S; Evoli A; Gilhus NE; Illa I; Harms L; Hilton-Jones D; Melms A; Verschuuren J; Horge HW;
Eur J Neurol; 2010 Jul; 17(7):893-902. PubMed ID: 20402760
[TBL] [Abstract][Full Text] [Related]
2. Guidelines for the treatment of autoimmune neuromuscular transmission disorders.
Skeie GO; Apostolski S; Evoli A; Gilhus NE; Hart IK; Harms L; Hilton-Jones D; Melms A; Verschuuren J; Horge HW
Eur J Neurol; 2006 Jul; 13(7):691-9. PubMed ID: 16834699
[TBL] [Abstract][Full Text] [Related]
3. Autoimmune mediated neuromuscular junction defects.
Farrugia ME; Vincent A
Curr Opin Neurol; 2010 Oct; 23(5):489-95. PubMed ID: 20651592
[TBL] [Abstract][Full Text] [Related]
4. Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
Newsom-Davis J
Semin Neurol; 2003 Jun; 23(2):191-8. PubMed ID: 12894384
[TBL] [Abstract][Full Text] [Related]
5. Paraneoplastic syndromes of the neuromuscular junction: therapeutic options in myasthenia gravis, lambert-eaton myasthenic syndrome, and neuromyotonia.
van Sonderen A; Wirtz PW; Verschuuren JJ; Titulaer MJ
Curr Treat Options Neurol; 2013 Apr; 15(2):224-39. PubMed ID: 23263888
[TBL] [Abstract][Full Text] [Related]
6. Update on the evaluation and therapy of autoimmune neuromuscular junction disorders.
Katz J; Barohn RJ
Phys Med Rehabil Clin N Am; 2001 May; 12(2):381-97. PubMed ID: 11345014
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune disorders of the neuromuscular junction.
Lang B; Vincent A
Curr Opin Pharmacol; 2009 Jun; 9(3):336-40. PubMed ID: 19428298
[TBL] [Abstract][Full Text] [Related]
8. Clinical aspects of neuromuscular transmission disorders.
Evoli A
Acta Neurol Scand Suppl; 2006; 183():8-11. PubMed ID: 16637919
[TBL] [Abstract][Full Text] [Related]
9. Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders.
Verschuuren JJ; Palace J; Murai H; Tannemaat MR; Kaminski HJ; Bril V
Lancet Neurol; 2022 Feb; 21(2):189-202. PubMed ID: 35065041
[TBL] [Abstract][Full Text] [Related]
10. Autoimmune disorders of neuromuscular transmission.
Mahadeva B; Phillips LH; Juel VC
Semin Neurol; 2008 Apr; 28(2):212-27. PubMed ID: 18351523
[TBL] [Abstract][Full Text] [Related]
11. [Immunologic aspects of disorders of neuromuscular transmission. 2. Experimental autoimmune myasthenia gravis and the Lambert-Eaton myasthenic syndrome].
Andreis I; Lovnićki TJ; Beara N; Taradi M
Lijec Vjesn; 1994; 116(5-6):158-61. PubMed ID: 7968205
[TBL] [Abstract][Full Text] [Related]
12. Myasthenia gravis and myasthenic syndrome.
Antozzi C
Neurol Sci; 2003 Oct; 24 Suppl 4():S260-3. PubMed ID: 14598056
[TBL] [Abstract][Full Text] [Related]
13. Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment.
Quartel A; Turbeville S; Lounsbury D
Curr Med Res Opin; 2010 Jun; 26(6):1363-75. PubMed ID: 20377318
[TBL] [Abstract][Full Text] [Related]
14. Autoantibodies to ion channels at the neuromuscular junction.
Lang B; Vincent A
Autoimmun Rev; 2003 Mar; 2(2):94-100. PubMed ID: 12848965
[TBL] [Abstract][Full Text] [Related]
15. Update in the Management of Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome.
Bodkin C; Pascuzzi RM
Neurol Clin; 2021 Feb; 39(1):133-146. PubMed ID: 33223079
[TBL] [Abstract][Full Text] [Related]
16. IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status.
Illa I
J Neurol; 2005 May; 252 Suppl 1():I14-8. PubMed ID: 15959667
[TBL] [Abstract][Full Text] [Related]
17. [The pathophysiology and treatment of autoimmune neuromuscular junction diseases].
Motomura M
Rinsho Shinkeigaku; 2011 Nov; 51(11):872-6. PubMed ID: 22277398
[TBL] [Abstract][Full Text] [Related]
18. Immunoadsorption in patients with autoimmune ion channel disorders of the peripheral nervous system.
Antozzi C
Atheroscler Suppl; 2013 Jan; 14(1):219-22. PubMed ID: 23357168
[TBL] [Abstract][Full Text] [Related]
19. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
Maddison P; McConville J; Farrugia ME; Davies N; Rose M; Norwood F; Jungbluth H; Robb S; Hilton-Jones D
J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):671-3. PubMed ID: 20392977
[TBL] [Abstract][Full Text] [Related]
20. Myasthenia gravis and Lambert-Eaton myasthenic syndrome.
Sanders DB; Guptill JT
Continuum (Minneap Minn); 2014 Oct; 20(5 Peripheral Nervous System Disorders):1413-25. PubMed ID: 25299290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
